OncoMatch/Clinical Trials/NCT06633601
MRI-Guided Ultrasound Stimulated Microbubbles Radiation Treatment for Patients with Chest-Wall and Locally Advanced Breast Cancer
Is NCT06633601 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including MR-Guided Focused Ultrasound Technology and Definity Suspension for for breast cancer.
Treatment: MR-Guided Focused Ultrasound Technology · Definity Suspension for — The objective of this study is to demonstrate the feasibility of novel Magnetic Resonance Imaging (MRI)-guided ultrasound stimulated microbubble treatment to enhance radiation effects in humans receiving external beam radiotherapy delivered using a LINAC (linear accelerator) radiation therapy device.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Breast Carcinoma
Disease stage
Required: Stage IIA, IIB, IIIA, IIIB, IIIC, IV
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: anthracycline
Patients having received anthracycline or taxane based chemotherapy within the past 5 days
Cannot have received: taxane
Patients having received anthracycline or taxane based chemotherapy within the past 5 days
Lab requirements
Kidney function
Creatinine within normal institutional limits or creatinine clearance >60mL/min/1.73m2 for patients with creatinine levels above institutional upper limit of normal. Severely impaired renal function with estimated glomerular filtration rate < 30ml/min/1.73m2 and/or on dialysis [excluded].
Cardiac function
Severe cardiovascular, cardiac disease or unstable hemodynamics including myocardial infarction within six months, unstable angina, congestive heart failure, cardiac shunts, cardiac arrhythmia and cardiac pacemaker [excluded]. Known QT prolongation (>450ms for men or >470ms for women) with cardiac impairment if ECG is requested as per SOC [excluded]. Contraindication to perflutren including subjects with a family or personal history of QT prolongation or taking concomitant medications known to cause QTc prolongation.
Creatinine within normal institutional limits or creatinine clearance >60mL/min/1.73m2 for patients with creatinine levels above institutional upper limit of normal. Severely impaired renal function with estimated glomerular filtration rate < 30ml/min/1.73m2 and/or on dialysis [excluded]. Severe cardiovascular, neurological, renal or hematological chronic disease [excluded]. Cardiac disease or unstable hemodynamics including myocardial infarction within six months, unstable angina, congestive heart failure, cardiac shunts, cardiac arrhythmia and cardiac pacemaker [excluded]. Known QT prolongation (>450ms for men or >470ms for women) with cardiac impairment if ECG is requested as per SOC [excluded].
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06633601 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior anthracycline, taxane disqualifies patients from enrollment.
What disease stage is eligible?
Stage IIA or IIB or IIIA or IIIB or IIIC or IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages